An Innovative, Paradigm-Shifting Lifestyle Intervention to Reduce Glucose Excursions With the Use of Continuous Glucose Monitoring to Educate, Motivate, and Activate Adults With Newly Diagnosed Type 2 Diabetes: Pilot Feasibility Study

Tamara K Oser¹, MD; Mark Cucuzzella², MD; Marilyn Stasinopoulos¹, MS; Matthew Moncrief³, BS; Anthony McCall⁴, MD, PhD; Daniel J Cox³, PhD

¹Department of Family Medicine, University of Colorado School of Medicine, Aurora, CO, United States
²Department of Family Medicine, West Virginia University School of Medicine, Morgantown, WV, United States
³Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, VA, United States
⁴Department of Medicine: Endocrinology and Metabolism, University of Virginia School of Medicine, Charlottesville, VA, United States

Corresponding Author:
Tamara K Oser, MD
Department of Family Medicine
University of Colorado School of Medicine
12631 East 17th Avenue F496
Academic Office One
Aurora, CO, 80045
United States
Phone: 1 303 724 2060
Email: tamara.oser@cuanschutz.edu

Abstract

Background: Type 2 diabetes (T2D) is a growing epidemic in the United States, and metabolic control has not been improved over the last 10 years. Glycemic excursion minimization (GEM) is an alternative lifestyle treatment option focused on reducing postnutrient glucose excursions rather than reducing weight. GEM has been proven to be superior to routine care when delivered face to face, and equivalent or superior to conventional weight loss therapy, but it has not been evaluated among patients newly diagnosed with T2D or in a self-administered format.

Objective: This pilot study evaluated the feasibility of a self-administered version of GEM, augmented with continuous glucose monitoring (CGM), to improve metabolic control (hemoglobin A₁c [HbA₁c]) while diminishing or delaying the need for diabetes medications in adults recently diagnosed with T2D. These primary objectives were hypothesized to be achieved by reducing carbohydrate intake and increasing physical activity to diminish CGM glucose excursions, leading to the secondary benefits of an increase in diabetes empowerment and reduced diabetes distress, depressive symptoms, and BMI.

Methods: GEM was self-administered by 17 adults recently diagnosed with T2D (mean age 52 years, SD 11.6 years; mean T2D duration 3.9 months, SD 2.5 months; mean HbA₁c levels 8.0%, SD 1.6%; 40% female; 33.3% non-White), with the aid of a 4-chapter pocket guide and diary, automated motivational text messaging, and feedback from an activity monitor, along with CGM and supplies for the 6-week intervention and the 3-month follow-up. Treatment was initiated with one telephone call reviewing the use of the technology and 3 days later with a second call reviewing the use of the GEM pocket guide and intervention.

Results: At 3-month follow-up, 67% of the participants’ diabetes was in remission (HbA₁c levels <6.5%), and only one participant started taking diabetes medication. Participants demonstrated a significant reduction in HbA₁c levels (~1.8%; P<.001). Participants also experienced significant reductions in high-glycemic-load carbohydrates routinely consumed, CGM readings that were >140 mg/dL, diabetes distress, depressive symptoms, and BMI. Participants felt that use of the CGM was the most significant single element of the intervention.

Conclusions: GEM augmented with CGM feedback may be an effective initial intervention for adults newly diagnosed with T2D. A self-administered version of GEM may provide primary care physicians and patients with a new tool to help people...
recently diagnosed with T2D achieve remission independent of medication and without weight loss as the primary focus. Future research is needed with a larger and more diverse sample.

(JMIR Diabetes 2022;7(1):e34465) doi: 10.2196/34465

KEYWORDS

type 2 diabetes; continuous glucose monitoring; glycemic excursion minimization; initial treatment; diabetes distress; diabetes; monitoring; treatment; distress; pilot study; lifestyle; intervention; motivation.

Introduction

Type 2 diabetes (T2D) is an epidemic in the United States, with 1.5 million new cases diagnosed annually, 34 million patients currently with the condition, and costing the US economy US $327 billion annually [1]. While the American Diabetes Association recommends weight loss of at least 7% and at least 150 minutes per week of moderate to vigorous physical activity to help manage T2D [2], up to 15% of these patients do not need to lose weight [3], while others are either unwilling or unable to lose weight and to maintain weight loss [4]. Further, glycemic control has not improved over the past decade [5-7]. International and national guidelines recommend diabetes self-management education and support (DSMES) for people with T2D around the time of diagnosis, but DSMES at the time of diagnosis is severely underutilized (only 6.8% of privately insured individuals and 5% of Medicare individuals receive DSMES within the first 12 months of being diagnosed with T2D) [8]. We developed an alternative lifestyle treatment option, glycemic excursion minimization (GEM), focusing on reducing postprandial blood glucose (BG) excursions that contribute to both hemoglobin A1c (HbA1c) [9] and to cardiovascular disease [10,11]. Although not classified as DSMES, GEM presents an additional method that may empower people with diabetes to better understand the impact of food and exercise on their blood glucose levels. GEM has been administered as a face-to-face intervention to adults diagnosed with T2D within the past 10 years and was superior to routine care [12,13] and equivalent or superior to conventional weight loss therapy in regard to reduction of HbA1c levels, cardiovascular risk, and improvement in psychological function and BMI [14,15]. However, GEM has never been evaluated among patients newly diagnosed with T2D, in a self-administered format, outside of the University of Virginia, with automated daily text prompts. Such an intervention might not only improve metabolic control but also reduce the reliance on diabetes medications.

Given accessibility issues owing to the pandemic, we investigated the efficacy of a remote GEM delivery program. Given that earlier intervention of T2D has greater long-term benefits [16] and may provide access to more motivated persons [17], we focused on newly diagnosed patients. Given that GEM has only been evaluated at the University of Virginia, we [17], we focused on newly diagnosed patients. Given that GEM has never been evaluated among patients newly diagnosed with T2D, in a self-administered format, outside of the University of Virginia (n=6). Inclusion criteria were as follows: age of 35-85 years, HbA1c levels of 6.5%-11.5%, diagnosed with T2D within the past 12 months, not taking diabetes medication, no medical condition or medication that precludes reducing carbohydrates or walking 120 steps per minute for 10 minutes (eg, prednisone, severe neuropathy, cardiovascular disease, chronic obstructive pulmonary disease or emphysema, osteoarthritis, stroke, severe gastroparesis, ulcers, or food allergies), and ability to read English. Our age criteria aimed to select individuals most likely to be in control of their daily routine, HbA1c criteria aimed to ensure the diagnoses of T2D but to avoid individuals whose condition was so progressive that immediate medication management was indicated, the no diabetes medication criterion was essential to test the hypothesis that GEM would prevent or diminish the need for diabetes medication, and the remaining criteria aimed to ensure the feasibility of engaging in the comprehensive GEM lifestyle.

Methods

Ethics Approval

This study was performed in accordance with the principles of the Declaration of Helsinki. Ethical approval for this study was obtained from the University of Virginia Institutional Review Board for Health Sciences Research (protocol HSR200250).

Recruitment

To maximize external validity, one-third of the participants were recruited from each of three diverse centers: University of Virginia (n=5), University of Colorado (n=6), and West Virginia University (n=6). Inclusion criteria were as follows: age of 35-85 years, HbA1c levels of 6.5%-11.5%, diagnosed with T2D within the past 12 months, not taking diabetes medication, no medical condition or medication that precludes reducing carbohydrates or walking 120 steps per minute for 10 minutes (eg, prednisone, severe neuropathy, cardiovascular disease, chronic obstructive pulmonary disease or emphysema, osteoarthritis, stroke, severe gastroparesis, ulcers, or food allergies), and ability to read English. Our age criteria aimed to select individuals most likely to be in control of their daily routine, HbA1c criteria aimed to ensure the diagnoses of T2D but to avoid individuals whose condition was so progressive that immediate medication management was indicated, the no diabetes medication criterion was essential to test the hypothesis that GEM would prevent or diminish the need for diabetes medication, and the remaining criteria aimed to ensure the feasibility of engaging in the comprehensive GEM lifestyle.

Procedure

After signing a University of Virginia IRB-approved consent, each participant’s primary care physician or clinician was contacted to affirm that the participant met eligibility criteria and to provide written approval for participation. Next, participants were sent a weblink to complete a series of questionnaires (Baseline: routine consumption of high and low glycemic load foods [19]; psychological questionnaires to assess diabetes empowerment [20], diabetes distress (emotional and regimen) [21], and depressive symptoms [22]; and diabetes knowledge as it relates to GEM principles [23].

After completing questionnaires, participants were mailed a CGM reader and 4.5 months of sensor supplies, (FreeStyle Libre 2 CGM system), a Fitbit Charge 3 activity monitor, and the GEM pocket guide (hard copy). This was followed by a telephone call introducing them to the CGM and activity monitor technology, inserting the CGM sensor, registering and activating.
the technology, and selecting seven personalized text messages, for example, “Food choices are life choices, Exercise is my friend,” which would be delivered at a time and frequency selected by the participant, to encourage GEM engagement [18]. Three days later, they received the second and final call to review the GEM pocket guide to initiate treatment.

GEM is neither a behavior modification nor a prescription program. Rather, GEM is an empowerment program [24,25] that provides information that a patient can choose to employ, to identify food and activity choices that either exacerbate or diminish postnutrient glucose excursions (represented by the area under the curve in Figure 1). The GEM pocket guide is a 4.25×5.50-inch booklet with four units. In unit 1, with CGM feedback, participants spend 5 days learning which of their routine food and physical activity choices have major and minor impacts on their glucose excursions. In unit 2 participants spend 14 days focusing on reducing, substituting, replacing, or eliminating high impact carbohydrates to diminish glucose excursions; for example, replacing breakfast oatmeal with unsweetened Greek yogurt and fresh fruit or substituting cauliflower rice for white rice. In unit 3, participants spend 14 days learning how to hasten recovery of glucose excursions by changing the type, intensity, duration, and timing of routine physical activity, such as walking the dog after supper instead of sitting in front of the television or computer. In unit 4, participants learn to continue experimenting with new nutrients and activities, sustain support of significant others, and prevent, anticipate, and recover from relapses resulting from fatigue, life stress, or change in routine. GEM was executed in the context of self-monitoring with diary entries, personal feedback from the CGM and the activity monitor, and automated daily motivational text messages. Following unit 1, there were 5 diary pages, and following units 2-4, there were 14 days of diaries where participants recorded their food and activity choices and how these impacted their glucose excursions.

Figure 1 displays 2 days of pre- and post-CGM data for 1 participant, illustrating how GEM reduces glucose excursions. After this 6-week GEM program, for the next 3 months, participants continued exploring the principles of GEM with the assistance of their CGM and Fitbit feedback. A 3-month posttreatment assessment involved downloading their CGM data, and repeating the web-based questionnaires. Following completion of these questionnaires, participants rated how “helpful” different elements of the program were on a Likert scale (0=not helpful at all, 1=slightly helpful, 2=somewhat helpful, 3=very helpful, and 4=extremely helpful).

Investigators then extracted participants’ diagnostic and post-GEM HbA1c levels, BMI, and prescribed diabetes medications from their medical records (Figure 2).
Figure 2. Timeline from diagnoses through follow-up assessment. GEM: glycemic excursion minimization.

| Months: | 0 | 4 | 5 | 8 |
|---------|---|---|---|---|
| Diagnosis | Consent | GEM Treatment | Follow-up |
| Baseline | Unit 1, day 3 Unit 2, day 19 Unit 3, day 33 Unit 4 | 3 mo. post |

Statistical Analysis

SPSS (version 27, IBM Corp) was used to perform 2-tailed paired t tests to test for differences in means between GEM participants’ diagnostic (baseline, preintervention) and 3-month postintervention data among the following outcome variables: HbA\(_1c\) levels, metformin dose, number of CGM readings that were >140 mg/dL, CGM glucose variability expressed as SD values [26,27], BMI, and weight. Pre- and postintervention mean scores were also compared for the following questionnaires or scales: high-carbohydrate food intake, low-carbohydrate food intake, diabetes knowledge, diabetes empowerment, diabetes distress (emotional subscale), diabetes distress (regimen subscale), and depressive symptoms. The Benjamini-Hochberg procedure [28] was used to control for multiple comparisons, correcting for all \(P\) values in Table 1. Exploratory Pearson correlations were performed between HbA\(_1c\) levels and both baseline and postintervention variables. There were no missing data, and none of the data sets violated the assumptions of a normal distribution.

Results

Participants’ mean age at diagnosis was 52 (SD 11.6) years, the mean time between diagnosis and consent was 3.9 (SD 2.5) months, the mean duration of diabetes at postintervention assessment was 8.5 (SD 3.3) months, 40% of participants were female, and 33.3% of participants were non-White. Table 1 provides more detailed baseline data. There was 1 adverse event (contact dermatitis from CGM sensor adhesive) and 2 dropouts (owing to oral surgery and family crisis).

Table 1 illustrates that at 3 months follow-up, GEM led to a significant reduction in HbA\(_1c\) levels (\(P<.001\)), with 66.7% of participants qualifying as having their diabetes in remission (HbA\(_1c\) level <6.5%) [29]. Further, 80% of the participants were classified as Responders (decrease in HbA\(_1c\) levels of at least 0.5%), with a mean pre-post change in HbA\(_1c\) levels of \(-2.3\%\) (SD 1.3%).
Table 1. Variables, pretreatment, and 3 months post–glycemic excursion minimization intervention.

| Variable                                | Pretreatment | 3 months post–glycemic excursion minimization | P value | Baseline correlation with change in hemoglobin A\textsubscript{1c} levels | Change in correlation with change in hemoglobin A\textsubscript{1c} levels |
|-----------------------------------------|--------------|-----------------------------------------------|---------|-------------------------------------------------------------------|------------------------------------------------------------------|
| Primary outcome variables, mean (SD)    |              |                                               |         |                                                                   |                                                                  |
| Hemoglobin A\textsubscript{1c} levels (%)| 8.0 (1.6)    | 6.2 (1.1)                                     | <.001\textsuperscript{a} | −0.755\textsuperscript{b}                                          |                                                                  |
| Metformin (mg/day)                       | 0 (0)        | 133 (516)                                     | .33     |                                                                   | −0.219                                                           |
| Mechanism variables                     |              |                                               |         |                                                                   |                                                                  |
| Continuous glucose monitoring data, unblinded weeks 1 and 18, mean (SD) |              |                                               |         |                                                                   |                                                                  |
| Percentage of time when continuous glucose monitoring values were >140 mg/dL | 23.9 (28.9)  | 14.5 (22)                                     | .03     | −0.012                                                            | −0.086                                                           |
| Glucose variability                      | 22.4 (10.1)  | 20.2 (8.3)                                     | .08     | 0.132                                                             | −0.208                                                           |
| High-carbohydrate foods                  | 39.6 (21.9)  | 10.3 (6.8)                                     | <.001\textsuperscript{a} | −0.243                                                            | 0.238                                                            |
| Low–carbohydrate foods                   | 50.2 (20.8)  | 48.6 (20.0)                                    | .69     | −0.413                                                            | 0.635\textsuperscript{c}                                         |
| Secondary benefits, mean (SD)            |              |                                               |         |                                                                   |                                                                  |
| Diabetes knowledge                       | 15.5 (3.0)   | 15.9 (3.0)                                     | .53     | 0.061                                                             | 0.555\textsuperscript{c}                                         |
| Diabetes empowerment                      | 31.0 (5.9)   | 34.6 (3.8)                                     | .06     | −0.253                                                            | 0.251                                                            |
| Diabetes distress, emotional             | 2.2 (0.8)    | 1.8 (1.0)                                      | .10     | −0.580\textsuperscript{c}                                         | 0.015                                                            |
| Diabetes distress, regimen               | 2.8 (1.4)    | 1.8 (0.9)                                      | .03     | 0.363                                                             | −0.052                                                           |
| Depressive symptoms                      | 6.1 (4.5)    | 2.3 (3.9)                                      | .001\textsuperscript{a} | 0.400                                                             | 0.132                                                            |
| BMI                                      | 36.5 (8.1)   | 34.4 (8.2)                                     | .002\textsuperscript{a} | 0.013                                                             | 0.333                                                            |

\textsuperscript{a}Significant with the Benjamini-Hochberg procedure.
\textsuperscript{b}Correlation with P<.01.
\textsuperscript{c}Correlation with P<.05.

Three months post GEM, participants presented reduced CGM readings >140 mg/dL (P=.03) and consumed high-carbohydrate foods routinely (P<.001). Secondary benefits included reduction of depressive symptoms (P=.001) and BMI (P=.002).

Table 1 additionally presents correlations of baseline variables with post-GEM reduction in HbA\textsubscript{1c} levels. Change in HbA\textsubscript{1c} levels was negatively correlated with baseline HbA\textsubscript{1c} levels (r=−0.755) and emotional diabetes distress (r=−0.580). The last column in Table 1 shows how improvement in variables correlated with improvement in HbA\textsubscript{1c} levels. Greater increase in diabetes knowledge (r=0.555) and greater increase in routine intake of low glycemic foods (r=0.635) were associated with greater improvement in HbA\textsubscript{1c} levels.

Reduction in HbA\textsubscript{1c} levels was only associated with higher baseline HbA\textsubscript{1c} levels (r=−0.755) and emotional diabetes distress (r=−0.580). Greater reduction in HbA\textsubscript{1c} levels was associated with greater pre-post reduction in low-glycemic-load carbohydrate ingestion (r=0.635) and improved diabetes knowledge (r=0.555).

Posttreatment mean ratings (0-4) for how helpful each of the different elements were: Libre 2 CGM=3.9, Fitbit=3.4, GEM Pocket Guide=2.9, diaries=2.6, GEM Supplement=2.5, and text messages=2.4.

Discussion

Principal Findings

Our primary hypotheses were confirmed. Mean HbA\textsubscript{1c} levels were reduced by 1.8% among all participants, with 67% being classified as having diabetes remission and 80% being classified as responders with a mean HbA\textsubscript{1c} level reduction of −2.3% among responders. This was achieved with only one participant needing to start taking medication. This participant’s HbA\textsubscript{1c} level decreased 3.6%, from 12.7% to 9.1%, which was a clinically important improvement that subsequently required the additional introduction of metformin.

Regarding secondary hypotheses, there was a posttreatment decrease in diabetes distress, depression symptoms, and BMI, and a trend toward increased diabetes empowerment.

The strengths of this study are that it was a multicenter, brief, self-administered intervention, which recruited a diverse sample by diverse investigators. The mean change in HbA\textsubscript{1c} levels of −1.8% by these GEM participants incorporating CGM compares favorably to the −1.0% change in HbA\textsubscript{1c} levels by a similar group in a randomized controlled trial delivered in a face-to-face format with adults having T2D for an average of 5.3 years of taking diabetes medication [12].
Limitations
Limitations of our study include a small sample size, no control group, and a limited follow-up duration. Additionally, pre-post change in physical activity, a presumed primary mechanism of GEM, was not monitored in this study. Despite these limitations and multiple positive findings, this is still a pilot study in need of replication with a larger and more diverse sample, which could tease out whether CGM alone would lead to such benefits.

Comparison With Prior Work
This compares favorably to a mean reduction in HbA1c levels of 1.5% and no psychological benefits with maximum dosage of metformin [30].

Despite being a self-directed program, these results were better than any of our previous efforts [12,15]. This could have resulted from our subject sample consisting of recently diagnosed adults who had not yet begun diabetes medication. This speculation is supported by the UK Prospective Diabetes Study [31], which initiated treatment for newly diagnosed T2D with 3 months of “dietary counseling” alone, with no medication, which led to a reduction in HbA1c levels by ~1%. It could also be because of all participants in this study wanting this intervention—no random assignment. However, it may also be due to the multidimensional nature of the intervention: feedback from CGM and activity monitors, a structured and brief pocket guide and diary, and daily text messages, all of which were considered helpful by participants. It could have been that a reduction in HbA1c levels was highly associated with baseline HbA1c levels, since those with a higher HbA1c level had the possibility of lowering it further, or that greater diabetes distress was associated with greater reduction, as this could reflect greater motivation. Likewise, the greater knowledge acquired about the impact of diet and activity on diabetes, and the greater reduction in routine carbohydrate ingestion were associated with more reduction in HbA1c levels, as these were the hypothesized mechanisms. Reduction in BMI was a secondary benefit and was not correlated with improvement in HbA1c levels.

Conclusions
GEM augmented with CGM feedback may be an effective initial intervention for adults newly diagnosed with T2D. A self-administered version of GEM may provide primary care physicians and their patients with a new tool to help people recently diagnosed with T2D to achieve remission independent of medication and without weight loss as the primary focus. Future research is needed with a larger and more diverse sample.

Acknowledgments
We would like to thank Dr Yogesh Yadav, research fellow at the Division of Endocrinology at the University of Virginia, for his assistance in data retrieval from patient records, and Dr Mark Conaway, professor at the Division of Translational Research and Applied Statistics in the Department of Public Health Sciences at the University of Virginia for his oversight of our data analyses. Abbott provided continuous glucose monitoring supplies for the trial. Abbott had no approval authority for the manuscript before submission. Data management, monitoring, and analysis were the responsibility of Virginia and were independent of the sponsor.

Conflicts of Interest
The funding sources were not involved in the design or conduct of the study, or in the preparation of this manuscript. TKO has served on a physician advisory board for Cecilia Health and Dexcom.

References
1. National Diabetes Statistics Report. Centers for Disease Control and Prevention. URL: https://www.cdc.gov/diabetes/data/statistics-report/index.html [accessed 2022-02-02]
2. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018 Dec;41(12):2669-2701 [FREE Full text] [doi: 10.2337/dc18-0033] [Medline: 30291106]
3. George AM, Jacob AG, Fogelfeld L. Lean diabetes mellitus: An emerging entity in the era of obesity. World J Diabetes 2015 May;15(6):613-620 [FREE Full text] [doi: 10.4239/wjd.v6i4.613] [Medline: 25987958]
4. Apolzan JW, Venditti EM, Edelstein SL, Knowler WC, Dabelea D, Boyko EJ. Diabetes Prevention Program Research Group. Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med 2019 May 21;170(10):682-690 [FREE Full text] [doi: 10.7326/M18-1605] [Medline: 31009939]
5. Ali MK, Bullard KM, Saadidine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013 Apr 25;368(17):1613-1624. [doi: 10.1056/NEJMsa1213829] [Medline: 23614587]
6. Carls G, Huynh J, Tuttle E, Yee J, Edelman SV. Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. Diabetes Ther 2017 Aug;8(4):863-873 [FREE Full text] [doi: 10.1007/s13300-017-0280-5] [Medline: 28646411]
7. Diabetes control worsened over the past decade. National Institutes of Health. 2021 Jun 29. URL: https://www.nih.gov/news-events/nihs-research-matters/diabetes-control-worsened-over-past-decade [accessed 2022-02-02]
8. Strawbridge L, Lloyd J, Meadow A, Riley G, Howell B. One-Year Outcomes of Diabetes Self-Management Training Among Medicare Beneficiaries Newly Diagnosed With Diabetes. Med Care 2017 Apr;55(4):391-397. [doi: 10.1097/MLR.0000000000000653] [Medline: 27753746]

9. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003 Mar;26(3):881-885. [doi: 10.2337/diacare.26.3.881] [Medline: 12610053]

10. Cavallet F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006 Mar;91(3):813-819. [doi: 10.1210/jc.2005-1005] [Medline: 16352690]

11. Aryangat AV, Gerich JE. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. Vasc Health Risk Manag 2010 Mar 24;6:145-155 [FREE Full text] [doi: 10.2147/vhrm.s8216] [Medline: 20448799]

12. Cox D, Oser T, Moncrief M, Conaway M, McCall A. Long-term follow-up of a randomized clinical trial comparing glycemic excursion minimization (GEM) to weight loss (WL) in the management of type 2 diabetes. BMJ Open Diabetes Res Care 2021 Nov;9(2):e002403 [FREE Full text] [doi: 10.1136/bmjdrc-2021-002403] [Medline: 34845062]

13. Cox D, Banton T, Moncrief M, Diamond A, McCall A. Minimizing Glucose Excursions (GEM) With Continuous Glucose Monitoring in Type 2 Diabetes: A Randomized Clinical Trial. J Endocr Soc 2020 Nov 01;4(11):bbv118 [FREE Full text] [doi: 10.1210/endo/bbv118] [Medline: 33094208]

14. Cox DJ, Taylor AG, Singh H, Moncrief M, Diamond A, Yancy WS, et al. Glycemic load, exercise, and monitoring blood glucose (GEM): A paradigm shift in the treatment of type 2 diabetes mellitus. Diabetes Res Clin Pract 2016 Jan;111:28-35. [doi: 10.1016/j.diabres.2015.10.021] [Medline: 26556234]

15. Cox DJ, Banton T, Moncrief M, Conaway M, Diamond A, Holmes V, et al. Glycemic excursion minimization in the management of type 2 diabetes: a novel intervention tested in a randomized clinical trial. BMJ Open Diabetes Res Care 2020 Dec;8(2):e001795 [FREE Full text] [doi: 10.1136/bmjdrc-2020-001795] [Medline: 33328160]

16. Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Diabetes Care 2021 Jul 07;44(10):2231-2237 [FREE Full text] [doi: 10.2337/dc20-2439] [Medline: 34244332]

17. Christensen NI, Drejer S, Burns K, Lundstrøm SL, Hempler NF. A Qualitative Exploration of Facilitators and Barriers for Diabetes Self-Management Behaviors Among Persons with Type 2 Diabetes from a Socially Disadvantaged Area. Patient Prefer Adherence 2020;14:569-580 [FREE Full text] [doi: 10.2147/PPA.S237631] [Medline: 32210542]

18. Nelson LA, Speiker A, Greevy R, LeStourgeon LM, Wallston KA, Mayberry LS. User Engagement Among Diverse Adults in a 12-Month Text Message-Delivered Diabetes Support Intervention: Results from a Randomized Controlled Trial. JMIR Mhealth Uhealth 2020 Jul 21;8(7):e17534 [FREE Full text] [doi: 10.2196/17534] [Medline: 32706738]

19. Cox D, Moncrief MA, Banton T, Ngo VM, Singh H, Diamond AM, et al. 806-P: Quantifying Carbohydrate Intake: A Reliable, Valid, Sensitive Alternative to 24-Hour Dietary Recall. Diabetes 2019 Jun 04;68(Supplement 1):806-P. [doi: 10.2337/db19-806-P]

20. Anderson RM, Funnell MM, Fitzgerald JT, Marrero DG. The Diabetes Empowerment Scale: a measure of psychosocial self-efficacy. Diabetes Care 2000 Jun;23(6):739-743. [doi: 10.2337/diacare.23.6.739] [Medline: 10840988]

21. Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care 2005 Mar;28(3):626-631. [doi: 10.2337/diacare.28.3.626] [Medline: 15753199]

22. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001 Sep;16(9):606-613 [FULL TEXT] [doi: 10.1046/j.1525-1594.2001.016009606.x] [Medline: 11556941]

23. Dunn D, Bryson J, Hoskins P, Alford J, Handelsman DJ, Turtle J. Development of the diabetes knowledge (DKN) scales: forms DKN-A, DKN-B, and DKN-C. Diabetes Care 1984;7(1):36-41. [doi: 10.2337/diacare.7.1.36] [Medline: 6705664]

24. Anderson R, Funnell M, Carlson A, Saleh-Statin N, Craddock S, Skinner TC. Facilitating Self-care Through Empowerment. In: Snoek FJ, Skinner TC, editors. Psychology in Diabetes Care. Hoboken, NJ: John Wiley & Sons; Apr 19, 2000.

25. Hernandez-Tejada MA, Campbell JA, Walker RJ, Smalls BL, Davis KS, Egde LE. Diabetes empowerment, medication adherence and self-care behaviors in adults with type 2 diabetes. Diabetes Technol Ther 2012 Jul;14(7):630-634 [FULL text] [doi: 10.1089/dia.2011.0287] [Medline: 22524548]

26. Shah VN, DuBose SN, Li Z, Beck RW, Peters AL, Weinstock RS, et al. Continuous Glucose Monitoring Profiles in Healthy Nonobese Participants: A Multicenter Prospective Study. J Clin Endocrinol Metab 2019 Oct 01;104(10):4356-4364 [FREE Full text] [doi: 10.1210/jc.2018-02763] [Medline: 31127824]

27. Shivapradas C, Aiswarya Y, Kejai S, Sridevi A, Anupam B, Ramdas B, et al. Comparison of CGM-Derived Measures of Glycemic Variability Between Pancreatogenic Diabetes and Type 2 Diabetes Mellitus. J Diabetes Sci Technol 2021 Jan;15(1):134-140 [FREE Full text] [doi: 10.1177/1932296819860133] [Medline: 31282179]

28. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Series B Stat Methodol 2018 Dec 05;57(1):289-300. [doi: 10.1111/j.2517-6161.1995.tb02031.x]
29. Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia 2021 Nov;64(11):2359-2366. [doi: 10.1007/s00125-021-05542-z] [Medline: 34458934]

30. Alexopoulos A, Yancy WS, Edelman D, Coffman CJ, Jeffreys AS, Maciejewski ML, et al. Clinical associations of an updated medication effect score for measuring diabetes treatment intensity. Chronic Illn 2021 Dec;17(4):451-462 [FREE Full text] [doi: 10.1177/1742395319884096] [Medline: 31653175]

31. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 Sep 12;332(9131):837-853. [Medline: 9742976]

Abbreviations

- **BG**: blood glucose
- **CGM**: continuous glucose monitoring
- **DSMIES**: diabetes self-management education and support
- **GEM**: glycemic excursion minimization
- **HbA1c**: hemoglobin A1c
- **T2D**: type 2 diabetes

©Tamara K Oser, Mark Cucuzzella, Marilyn Stasinopoulos, Matthew Moncrief, Anthony McCall, Daniel J Cox. Originally published in JMIR Diabetes (https://diabetes.jmir.org), 23.02.2022. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Diabetes, is properly cited. The complete bibliographic information, a link to the original publication on https://diabetes.jmir.org/, as well as this copyright and license information must be included.